Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
FLUCONAZOLE
TARO PHARMACEUTICALS INC
J02AC01
FLUCONAZOLE
50MG
TABLET
FLUCONAZOLE 50MG
ORAL
30
Prescription
AZOLES
Active ingredient group (AIG) number: 0122529001; AHFS:
APPROVED
2004-02-27
Taro-Fluconazole (Fluconazole Tablets) Page 1 of 55 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr TARO-FLUCONAZOLE Fluconazole Tablets Tablets, 50 mg, 100 mg and 200 mg, oral Antifungal Agent Taro Pharmaceuticals Inc. Date of Initial Authorization 130 East Drive February 27, 2004 Brampton, Ontario L6T 1C1 Date of Revision: October 25, 2022 Control Number: 267711 Taro-Fluconazole (Fluconazole Tablets) Page 2 of 55 RECENT MAJOR LABEL CHANGES 1 INDICATIONS 10/2022 2 CONTRAINDICATIONS 10/2022 4 DOSAGE AND ADMINISTRATION, 4.4 Missed Dose 10/2022 7 WARNINGS AND PRECAUTIONS 10/2022 9 DRUG INTERACTIONS 10/2022 13 PHARMACEUTICAL INFORMATION 10/2022 15 MICROBIOLOGY 10/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ................................................................................................................. 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics................................................................................................................... 4 2 CONTRAINDICATIONS...................................................................................................... 5 4 DOSAGE AND ADMINISTRATION ..................................................................................... 5 4.1 Dosing Considerations ............................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ............................................................ 5 4.4 Missed Dose .. Baca dokumen lengkapnya